Cabazitaxel As a Promising Therapy for Cisplatin-resistant Bladder Cancer: a Preliminary Study

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Aug 6

PMID 39105986

Authors

Asim Joshi

Abantika Ghosh

Prashant Rai

Sarika Tilwani

Venkataramanan Ramachandran

Kumar Prabhash

Mahul Amin

Prashant Kumar

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is a common malignancy worldwide, posing a substantial healthcare challenge. Current standard treatment regimens are primarily based on cisplatin, but their success is often limited by cisplatin resistance and associated toxicities. Therefore, there is an urgent need to develop effective and less toxic therapies as alternatives to cisplatin. We screened the activity of FDA-approved anti-cancer drugs on a panel of cisplatin-resistant bladder cancer cell lines. Based on initial responses, cabazitaxel was selected for further evaluation of its inhibitory effects on the phenotypic properties of these cells. Cabazitaxel, primarily used for metastatic castration-resistant prostate cancer, demonstrated remarkable efficacy in inhibiting colony formation, proliferation, and migration of cisplatin-resistant bladder cancer cells. This study highlights the potential of drug repurposing as a cost-effective and efficient strategy to overcome drug resistance in bladder cancer.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

Teply B, Kim J . Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors. 2014; 4(2):25-35. PMC: 4232954. DOI: 10.5430/jst.v4n2p25. View

Desilets A, Adam J, Soulieres D . Management of cisplatin-associated toxicities in bladder cancer patients. Curr Opin Support Palliat Care. 2020; 14(3):286-292. DOI: 10.1097/SPC.0000000000000505. View

Morales-Barrera R, Bellmunt J, Suarez C, Valverde C, Guix M, Serrano C . Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012; 48(12):1816-21. DOI: 10.1016/j.ejca.2012.04.002. View

Drayton R, Catto J . Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012; 12(2):271-81. DOI: 10.1586/era.11.201. View

Sathe G, George I, Deb B, Jain A, Patel K, Nayak B . Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1. Oncotarget. 2020; 11(34):3244-3255. PMC: 7456616. DOI: 10.18632/oncotarget.27696. View

Kumar P, Nandi S, Tan T, Ler S, Chia K, Lim W . Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 2015; 6(15):13539-49. PMC: 4537032. DOI: 10.18632/oncotarget.3841. View

10.

Sharma J, Deb B, George I, Kapil S, Coral K, Kakkar N . Somatic Mutations Profile of a Young Patient With Metastatic Urothelial Carcinoma Reveals Mutations in Genes Involved in Ion Channels. Front Oncol. 2019; 9:435. PMC: 6549525. DOI: 10.3389/fonc.2019.00435. View

11.

Shi Z, Hao L, Han X, Wu Z, Pang K, Dong Y . Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol Cancer. 2022; 21(1):37. PMC: 8819945. DOI: 10.1186/s12943-022-01517-9. View

12.

Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K . Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017; 8(1):2193. PMC: 5736752. DOI: 10.1038/s41467-017-02320-7. View

13.

Gopalakrishnan D, Koshkin V, Ornstein M, Papatsoris A, Grivas P . Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018; 14:1019-1040. PMC: 5993034. DOI: 10.2147/TCRM.S158753. View

14.

Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G . Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27(27):4454-61. DOI: 10.1200/JCO.2008.20.5534. View

15.

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M . Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019; 16(8):465-483. DOI: 10.1038/s41585-019-0208-0. View

16.

Zeegers M, Tan F, Dorant E, van den Brandt P . The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000; 89(3):630-9. DOI: 10.1002/1097-0142(20000801)89:3<630::aid-cncr19>3.3.co;2-h. View

17.

Felix A, Soliman A, Khaled H, Zaghloul M, Banerjee M, El-Baradie M . The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008; 19(4):421-9. PMC: 4274945. DOI: 10.1007/s10552-007-9104-7. View

18.

Crow P, Ritchie A . National and international variation in the registration of bladder cancer. BJU Int. 2003; 92(6):563-6. DOI: 10.1046/j.1464-410x.2003.04421.x. View

19.

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

20.

Leal J, Luengo-Fernandez R, Sullivan R, Witjes J . Economic Burden of Bladder Cancer Across the European Union. Eur Urol. 2015; 69(3):438-47. DOI: 10.1016/j.eururo.2015.10.024. View